Literature DB >> 7065944

Autosomal dominant vitreoretinochoroidopathy.

S J Kaufman, M F Goldberg, D H Orth, G A Fishman, H Tessler, K Mizuno.   

Abstract

Autosomal dominant vitreoretinochoroidopathy is a newly described fundus dystrophy characterized by abnormal chorioretinal hypopigmentation and hyperpigmentation, usually lying between the vortex veins and the ora serrata for 360 degrees. In this zone, there are a discrete posterior boundary, preretinal punctate white opacities, retinal arteriolar narrowing and occlusion, and, in some cases, choroidal atrophy. Most affected family members have diffuse retinal vascular incompetence, cystoid macular edema, and presenile cataracts. The vitreous is characterized by fibrillar condensation and a moderate number of cells. Electroretinograms are normal in younger affected individuals and are only moderately abnormal in older ones. Preretinal neovascularization, present in the posterior pole, is progressive in the proband. There are no identifiable systemic or skeletal abnormalities, high myopia, optically empty vitreous, lattice degeneration, areas of white-without-pressure, retinal breaks, or retinal detachment; thus, previously described vitreoretinopathies can be excluded from diagnostic consideration. Progression of this diagnostic seems to be extremely slow in most family members.

Entities:  

Mesh:

Year:  1982        PMID: 7065944     DOI: 10.1001/archopht.1982.01030030274008

Source DB:  PubMed          Journal:  Arch Ophthalmol        ISSN: 0003-9950


  18 in total

1.  [Criswick-Schepens syndrome -- familial exudative vitreoretinopathy. Report of six cases in two consanguineous families].

Authors:  A Alsheikheh; W Lieb; F Grehn
Journal:  Ophthalmologe       Date:  2004-09       Impact factor: 1.059

2.  BEST1-related autosomal dominant vitreoretinochoroidopathy: a degenerative disease with a range of developmental ocular anomalies.

Authors:  A Vincent; C McAlister; C Vandenhoven; E Héon
Journal:  Eye (Lond)       Date:  2010-11-12       Impact factor: 3.775

Review 3.  Bestrophin 1 and retinal disease.

Authors:  Adiv A Johnson; Karina E Guziewicz; C Justin Lee; Ravi C Kalathur; Jose S Pulido; Lihua Y Marmorstein; Alan D Marmorstein
Journal:  Prog Retin Eye Res       Date:  2017-01-30       Impact factor: 21.198

4.  Long-term changes in autosomal dominant vitreoretinochoroidopathy (ADVIRC).

Authors:  L Wöster; J Roider
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2017-10-03       Impact factor: 3.117

5.  Retinitis pigmentosa: clinical observations and correlations.

Authors:  R C Pruett
Journal:  Trans Am Ophthalmol Soc       Date:  1983

6.  Dominant exudative vitreoretinopathy and other vascular developmental disorders of the peripheral retina.

Authors:  C E van Nouhuys
Journal:  Doc Ophthalmol       Date:  1982-09-23       Impact factor: 2.379

7.  Three-dimensional distribution of the vitelliform lesion, photoreceptors, and retinal pigment epithelium in the macula of patients with best vitelliform macular dystrophy.

Authors:  Christine N Kay; Michael D Abramoff; Robert F Mullins; Tyson R Kinnick; Kyuongmoo Lee; Mari E Eyestone; Mina M Chung; Elliott H Sohn; Edwin M Stone
Journal:  Arch Ophthalmol       Date:  2011-11-14

Review 8.  Functional roles of bestrophins in ocular epithelia.

Authors:  Alan D Marmorstein; Harold E Cross; Neal S Peachey
Journal:  Prog Retin Eye Res       Date:  2009-05-04       Impact factor: 21.198

9.  Autosomal dominant vitreoretinochoroidopathy (ADVIRC).

Authors:  N P Blair; M F Goldberg; G A Fishman; T Salzano
Journal:  Br J Ophthalmol       Date:  1984-01       Impact factor: 4.638

10.  Missense mutations in a retinal pigment epithelium protein, bestrophin-1, cause retinitis pigmentosa.

Authors:  Alice E Davidson; Ian D Millar; Jill E Urquhart; Rosemary Burgess-Mullan; Yusrah Shweikh; Neil Parry; James O'Sullivan; Geoffrey J Maher; Martin McKibbin; Susan M Downes; Andrew J Lotery; Samuel G Jacobson; Peter D Brown; Graeme C M Black; Forbes D C Manson
Journal:  Am J Hum Genet       Date:  2009-10-22       Impact factor: 11.025

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.